BioNTech 2nd-qtr sales plummet, as the biotech turns in a loss

7 August 2023
biontech-large

Germany’s BioNTech (Nasdaq: BNTX), which shot into the limelight with the development of the first and most successful COVID-19 vaccine, Comirnaty, partnered with Pfizer (NYSE: PFE), today reported financial results for the three months ended June 30, 2023.

BioNTech shares were down more than 6% at $99.82 in pre-market activity following the announcement.

Total revenues reported were 167.7 million euros ($184.8 million) for the second quarter, well short of FactSet consensus of 628.1 million euros, and compared to 3,196.5 million euros for the comparative prior year period, as well as a swinging to a net loss of 190.4 million euros that beat forecasts. The earnings per share (EPS) loss was 0.79 euros, versus, 6.45 euros profit a share the year earlier.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology